When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a gaping hole in the top ...
One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...
AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback